James Mcarthur is a high-skilled expert, that works in Ra Capital Management L.p as a Venture Partner since 2020. This expert gained professional experience in more than 16 positions at various companies. James Mcarthur went to the University of California, Berkeley and was studying there from 2019 to 2019. Boston, Massachusetts is the area, where this professional was lastly known to be situated. This expert's contacts can be accessed through SoftwareOfficial on demand.
Name variants:
Jaymes Mcarthur,
Jaimes Mcarthur,
Jim Mcarthur,
Jimmy Mcarthur,
Jimmie Mcarthur,
Jamie Mcarthur,
Jem Mcarthur
Last updated May 22, 2024
Contact Information
Last Update
Jul 7, 2022
Email
jm**@comcast.net
Location
Boston, MA
Company
Ra Capital Management L.p
Workplace
Venture Partner
Work History
Founder
700 Technology Sq, Cambridge, MA 02139
Tiburo is developing new drugs for the treatment of rare neuroendocrine disorders. The lead program, enters phase 2 clinical trials in 2018, for the treatment of non-functioning pituitary ad...
from Jan 2019
President of Research and Development, Founder
700 Technology Sq, Cambridge, MA 02139
Cydan II (www.cydanco.com) is an orphan drug accelerator that creates new companies focussed on developing therapies for rare diseases. We identify promising assets with well-understood biol...
from Sep 2017
President of Research and Development, Founder
Cydan, LLC is an orphan drug accelerator that creates new companies focussed on developing therapies for rare diseases. We identify promising assets with well-understood biology and preclini...
Dec 2012 — Sep 2017
Venture Advisor
5425 Wisconsin Ave SUITE 800, Chevy Chase, MD 20815
Jan 1, 2014 — Mar 2017
Member Board of Directors, Founder
Imara Inc., is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that c...
from Jan 2016
Co Founder
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an or...
Sep 2014 — Jan 2015
Member of the Board of Directors and Scientific Advisory Board
533 west Uwchlan Ave, Downingtown, PA 19335
Member of the FARA SAB and BOD. Friedreich’s ataxia (FA) is a debilitating, life-shortening, degenerative neuro-muscular disorder. FARA is supporting research that will improve the quality a...
from Jun 2014
Chief Scientific Officer
Founding CSO. Invented and advanced through first-in-man studies, the SDP051 antibody, which targets Cadherin-11. Synovex renamed Adheron Therapeutics. SDP051 acquired by ROCHE for $580M in ...
Jun 2006 — Nov 2012
Principal Consultant
Massachusetts
Advisor to CEO and CMO. Worked with management team to define strategic plan. Established preclinical pharmacology program and lead assay development.
2009 — 2011
Principal Consultant
Cambridge, MA
Advisor to CEO. Interim head of R&D.
2007 — 2008
Vice President Research and Preclinical Development
Lead preclinical R&D on protein therapeutic to reduce bone and gut derived progenitor cell sensitivity to chemotherapy.
2001 — 2005
Senior Director Preclinical
24590 Clawiter Rd, Hayward, CA 94545
Created and led programs in oncology, immunology, virology and vascular disease. Led company's first T cell oncology therapy from bench to clinic in 3 years. Managed 50+ person research depa...
1996 — 2002
Senior Scientist
Research scientist in oncology, immunology and virology. Did translational research on viral based lung cancer vaccine and dendritic cell vaccine.
1993 — 1995
Education
2019 — 2019
1991 — 1993
1989 — 1991
1984 — 1989
1980 — 1984
Occupations
Executive
Partner
Scientist
Biotechnology Professional
Founder
Chief Executive
Biologist
Biological Scientist
Founding Member
Skills
Drug Development
Immunology
Biotechnology
Life Sciences
Oncology
Drug Discovery
R&D
Technology Transfer
Molecular Biology
Biochemistry
Cell Biology
Protein Chemistry
Cancer
Elisa
Preclincal Development
Research
Cell Based Assays